Skip Navigation

Center for Immunization Research

Left Background
 

Malaria Selected Publications


Ellis RD, Sagara I, Durbin A, Dicko A, Shaffer D, Miller L, Assadou MH, Kone M, Kamate B, Guindo O, Fay MP, Diallo DA, Doumbo OK, Emanuel EJ, Millum J. Comparing the understanding of subjects receiving a candidate malaria vaccine in the United States and Mali Am J Trop Med Hyg 2010 Oct 8 3;4: 868-72

Ellis RD, Martin LB, Shaffer D, Long CA, Miura K, Fay MP, Narum DL, Zhu D, Mullen GE, Mahanty S, Miller LH, Durbin AP. Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naive adults PLoS One 2010 Jan 22; 5(1):e8787

Ellis RD, Mullen GE, Pierce M, Martin LB, Miura K, Fay MP, Long CA, Shaffer D, Saul A, Miller LH, Durbin AP. A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals Vaccine 2009 Jun 24;27(31):4104-9 

Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51PLoS One 2008 Jul 9;3(7):e2636

Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE. 2008; 3(7):e2636.

Ellis RD, Sagara I, Durbin A, Dicko A, Shaffer D, Miller L, Assadou MH, Kone M, Kamate B, Guindo O, Fay MP, Diallo DA, Doumbo OK, Emanuel EJ, Millum J. Comparing the understanding of subjects receiving a candidate malaria vaccine in the United States and Mali Am J Trop Med Hyg 2010 Oct 8 3;4: 868-72

Ellis RD, Martin LB, Shaffer D, Long CA, Miura K, Fay MP, Narum DL, Zhu D, Mullen GE, Mahanty S, Miller LH, Durbin AP. Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naive adults PLoS One 2010 Jan 22; 5(1):e8787

Ellis RD, Mullen GE, Pierce M, Martin LB, Miura K, Fay MP, Long CA, Shaffer D, Saul A, Miller LH, Durbin AP. A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals Vaccine 2009 Jun 24;27(31):4104-9 

Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51PLoS One 2008 Jul 9;3(7):e2636

Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE. 2008; 3(7):e2636.

Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, Giersing BK, Mullen GE, Orbutt A, Awkal M, Zhou H, Want J, Stowers AW, Long CA, Mahanty S, Miller LH, Saul A, Durbin AP.  Phase 1 clinical trial of apical membrane antigen 1 (AMA1): An asexual blood stage vaccine for Plasmodium falciparum malaria. Infect Immun. 2005; 73(6):3677-3685.

Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers AW, Miller LH, Saul A. Phase 1 Vaccine Trial of Pvs25H:  A Transmission Blocking Vaccine for Plasmodium vivax Malaria. Vaccine. 2005; 23(24):3131-3138.